BI | pharmaphorum

News

Boehringer buys immunotherapy biotech AMAL Therapeutics

Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and vaccines in oncology.

News

Boehringer and Sarah Cannon team for immune-oncology venture

Partnership will seek to develop two immune checkpoint inhibitor candidates.

News

FDA cites 'significant concerns' with ADC lymphoma trial

ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

BI

Editor's Picks